Several new drugs treating the hepatitis C virus were approved by the FDA this year, with more on the way by the end of 2014 and into the beginning of 2015. This revolutionary new class of oral, direct-acting antiviral drugs is showing a much higher success rate in patients. The projected outcomes of these new therapies are:
- a greater tolerance for the treatment with less side effects
- a shorter treatment duration
- a higher number of patients achieving a sustained viral response.
Physicians in each of our six office locations are accepting referrals and are treating hepatitis C patients with these new drugs.